{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:50:54Z","timestamp":1770965454415,"version":"3.50.1"},"reference-count":52,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The use of myelosuppressive agents to reduce the risk of thrombosis in patients with polycythemia vera (PV) and essential thrombocythemia (ET) has been associated with an increased risk of transformation to acute myeloid leukemia (AML). Whereas chlorambucil, busulfan, and radiophosphorus (32P) have been demonstrated to increase the risk of transformation, the leukemogenic potential of hydroxyurea (HU) continues to be a matter of debate. Clinical studies have suggested that HU may cause a small increase in the risk of AML, but it has proven difficult to establish whether AML is actually caused by HU or arises during the natural progression of PV and ET. Reports that HU undergoes metabolic activation to species that induce mutation appear to support the notion that it is leukemogenic. Here, we suggest that the ability of HU to induce mutation in cell culture studies results from the generation of nitrogen dioxide via the autoxidation of nitric oxide, a product of HU metabolism. However, we argue that autoxidation would not occur in vivo, leading to the conclusion that generation of the mutagen nitrogen dioxide is peculiar to cell culture systems and has little relevance to the use of HU in the management of PV and ET.<\/jats:p>","DOI":"10.1182\/blood-2005-08-3429","type":"journal-article","created":{"date-parts":[[2005,11,11]],"date-time":"2005-11-11T01:24:39Z","timestamp":1131672279000},"page":"2219-2222","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":30,"title":["Nitric oxide generation from hydroxyurea: significance and implications for leukemogenesis in the management of myeloproliferative disorders"],"prefix":"10.1182","volume":"107","author":[{"given":"Mark J.","family":"Burkitt","sequence":"first","affiliation":[{"name":"From the Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom; and the Department of Haematology, Monklands Hospital, Airdrie, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alaeddin","family":"Raafat","sequence":"additional","affiliation":[{"name":"From the Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom; and the Department of Haematology, Monklands Hospital, Airdrie, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111711055567100_REF1","doi-asserted-by":"crossref","unstructured":"Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365: 1054-1061.","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"2019111711055567100_","doi-asserted-by":"crossref","unstructured":"Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7: 387-397.","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"2019111711055567100_REF3","doi-asserted-by":"crossref","unstructured":"James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature. 2005;434: 1144-1148.","DOI":"10.1038\/nature03546"},{"key":"2019111711055567100_REF4","doi-asserted-by":"crossref","unstructured":"Spivak JL, Barosi G, Tognoni G, et al. Chronic myeloproliferative disorders. Hematology. 2003; 200-224.","DOI":"10.1182\/asheducation-2003.1.200"},{"key":"2019111711055567100_REF5","doi-asserted-by":"crossref","unstructured":"Finazzi G, Barbui T. Risk-adapted therapy in essential thrombocythemia and polycythemia vera. Blood Rev. 2005;19: 243-252.","DOI":"10.1016\/j.blre.2005.01.001"},{"key":"2019111711055567100_REF6","doi-asserted-by":"crossref","unstructured":"Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2002;100: 4272-4290.","DOI":"10.1182\/blood-2001-12-0349"},{"key":"2019111711055567100_REF7","doi-asserted-by":"crossref","unstructured":"Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med. 1981;304: 441-447.","DOI":"10.1056\/NEJM198102193040801"},{"key":"2019111711055567100_REF8","doi-asserted-by":"crossref","unstructured":"Barbui T. The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both? Semin Hematol. 2004;41: 15-17.","DOI":"10.1053\/j.seminhematol.2004.02.006"},{"key":"2019111711055567100_REF9","doi-asserted-by":"crossref","unstructured":"Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005;105: 2664-2670.","DOI":"10.1182\/blood-2004-09-3426"},{"key":"2019111711055567100_REF10","doi-asserted-by":"crossref","unstructured":"Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353: 33-45.","DOI":"10.1056\/NEJMoa043800"},{"key":"2019111711055567100_REF11","doi-asserted-by":"crossref","unstructured":"Najean Y, Rain J-D. Treatment for polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood. 1997;90: 3370-3377.","DOI":"10.1182\/blood.V90.9.3370"},{"key":"2019111711055567100_REF12","doi-asserted-by":"crossref","unstructured":"Sterkers Y, Preudhomme C, Lai\u0308 J-L, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood. 1998;91: 616-622.","DOI":"10.1182\/blood.V91.2.616"},{"key":"2019111711055567100_REF13","doi-asserted-by":"crossref","unstructured":"Passamonti F, Lazzarino M. Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman. Leuk Lymphoma. 2003;44: 1483-1488.","DOI":"10.1080\/1042819031000090192"},{"key":"2019111711055567100_REF14","unstructured":"Li JC, Kaminskas E. Progressive formation of DNA lesions in cultured Ehrlich ascites tumor cells treated with hydroxyurea. Cancer Res. 1987;47: 2755-2758."},{"key":"2019111711055567100_REF15","doi-asserted-by":"crossref","unstructured":"Hanft VN, Fruchtman SR, Pickens CV, Rosse WF, Howard TA, Ware RE. Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood. 2000;95: 3589-3593.","DOI":"10.1182\/blood.V95.11.3589"},{"key":"2019111711055567100_REF16","doi-asserted-by":"crossref","unstructured":"Lassmann G, Liermann B. ESR studies of structure and kinetics of radicals from hydroxyurea. Free Radical Biol Med. 1989;6: 241-244.","DOI":"10.1016\/0891-5849(89)90050-6"},{"key":"2019111711055567100_REF17","doi-asserted-by":"crossref","unstructured":"Lepoivre M, Flaman J-M, Bobe\u0301 P, Lemaire G, Henry Y. Quenching of the tyrosyl free radical of ribonucleotide reductase by nitric oxide. J Biol Chem. 1994;269: 21891-21897.","DOI":"10.1016\/S0021-9258(17)31886-0"},{"key":"2019111711055567100_","doi-asserted-by":"crossref","unstructured":"Pacelli R, Taira J, Cook JA, Wink DA, Krishna MC. Hydroxyurea reacts with heme proteins to generate nitric oxide. Lancet. 1996;347: 900.","DOI":"10.1016\/S0140-6736(96)91378-1"},{"key":"2019111711055567100_","doi-asserted-by":"crossref","unstructured":"Jiang J, Jordan SJ, Barr DP, Gunther MR, Maeda H, Mason RP. In vivo production of nitric oxide in rats after administration of hydroxyurea. Mol Pharmacol. 1997;52: 1081-1086.","DOI":"10.1124\/mol.52.6.1081"},{"key":"2019111711055567100_","doi-asserted-by":"crossref","unstructured":"Sato K, Akaike T, Sawa T, et al. Nitric oxide generation from hydroxyurea via copper-catalyzed peroxidation and implications for pharmacological actions of hydroxyurea. Jpn J Cancer Res. 1997;88: 1199-1204.","DOI":"10.1111\/j.1349-7006.1997.tb00349.x"},{"key":"2019111711055567100_REF21","doi-asserted-by":"crossref","unstructured":"Huang J, Sommers EM, Kim-Shapiro DB, King SB. Horseradish peroxidase catalyzed nitric oxide formation from hydroxyurea. J Am Chem Soc. 2002;124: 3473-3480.","DOI":"10.1021\/ja012271v"},{"key":"2019111711055567100_REF22","doi-asserted-by":"crossref","unstructured":"Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol. 1996;271: C1424-C1437.","DOI":"10.1152\/ajpcell.1996.271.5.C1424"},{"key":"2019111711055567100_","doi-asserted-by":"crossref","unstructured":"Denicola A, Freeman BA, Trujillo M, Radi R. Peroxynitrite reaction with carbon dioxide\/bicarbonate: kinetics and influence on peroxynitrite-mediated oxidations. Arch Biochem Biophys. 1996;333: 49-58.","DOI":"10.1006\/abbi.1996.0363"},{"key":"2019111711055567100_","doi-asserted-by":"crossref","unstructured":"Squadrito GL, Pryor WA. Oxidative chemistry of nitric oxide: the roles of superoxide, peroxynitrite, and carbon dioxide. Free Radical Biol Med. 1998;25: 392-403.","DOI":"10.1016\/S0891-5849(98)00095-1"},{"key":"2019111711055567100_REF25","doi-asserted-by":"crossref","unstructured":"Radi R, Peluffo G, Alvarez MN, Naviliat M, Cayota A. Unraveling peroxynitrite formation in biological systems. Free Radical Biol Med. 2001;30: 463-488.","DOI":"10.1016\/S0891-5849(00)00373-7"},{"key":"2019111711055567100_REF26","doi-asserted-by":"crossref","unstructured":"Koppenol WH. The basic chemistry of nitrogen monoxide and peroxynitrite. Free Radical Biol Med. 1998;25: 385-391.","DOI":"10.1016\/S0891-5849(98)00093-8"},{"key":"2019111711055567100_REF27","doi-asserted-by":"crossref","unstructured":"Friebe A, Koesling D. Regulation of nitric oxide-sensitive guanylyl cyclase. Circ Res. 2003;93: 96-105.","DOI":"10.1161\/01.RES.0000082524.34487.31"},{"key":"2019111711055567100_REF28","unstructured":"Wardman P. Nitrogen dioxide in biology: correlating chemical kinetics with biological effects. In: Alfassi ZB, ed. N-Centered Radicals. London, United Kingdom: John Wiley & Sons; 1998: 155-179."},{"key":"2019111711055567100_REF29","doi-asserted-by":"crossref","unstructured":"Mikkelsen RB, Wardman P. Biological chemistry of reactive oxygen and nitrogen and radiation-induced signal transduction mechanisms. Oncogene. 2003;22: 5734-5754.","DOI":"10.1038\/sj.onc.1206663"},{"key":"2019111711055567100_REF30","doi-asserted-by":"crossref","unstructured":"Ioannidis I, Ba\u0308tz M, Kirsch M, Korth H-G, Sustmann R, de Groot H. Low toxicity of nitric oxide against endothelial cells under physiological oxygen partial pressures. Biochem J. 1998;329: 425-430.","DOI":"10.1042\/bj3290425"},{"key":"2019111711055567100_REF31","doi-asserted-by":"crossref","unstructured":"Nguyen T, Brunson D, Crespi CL, Penman BW, Wishnok JS, Tannenbaum SR. DNA damage and mutation in human cells exposed to nitric oxide in vitro. Proc Natl Acad Sci U S A. 1992;89: 3030-3034.","DOI":"10.1073\/pnas.89.7.3030"},{"key":"2019111711055567100_","doi-asserted-by":"crossref","unstructured":"Arroyo PL, Hatch-Pigott V, Mower HF, Cooney RV. Mutagenicity of nitric oxide and its inhibition by antioxidants. Mutation Res. 1992;281: 193-202.","DOI":"10.1016\/0165-7992(92)90008-6"},{"key":"2019111711055567100_REF33","doi-asserted-by":"crossref","unstructured":"Liu RH, Hotchkiss JH. Potential genotoxicity of chronically elevated nitric oxide: a review. Mutation Res. 1995;339: 73-89.","DOI":"10.1016\/0165-1110(95)90004-7"},{"key":"2019111711055567100_REF34","doi-asserted-by":"crossref","unstructured":"Timson J. Hydroxyurea. Mutation Res. 1975;32: 115-132.","DOI":"10.1016\/0165-1110(75)90002-0"},{"key":"2019111711055567100_REF35","doi-asserted-by":"crossref","unstructured":"Ziegler-Skylakakis K, Schwarz LR, Andrae U. Microsome- and hepatocyte-mediated mutagenicity of hydroxyurea and related aliphatic hydroxamic acids in V79 Chinese hamster cells. Mutation Res. 1985;152: 225-231.","DOI":"10.1016\/0027-5107(85)90065-X"},{"key":"2019111711055567100_REF36","doi-asserted-by":"crossref","unstructured":"Sakano K, Oikawa S, Hasegawa K, Kawanishi S. Hydroxyurea induces site-specific DNA damage via formation of hydrogen peroxide and nitric oxide. Jpn J Cancer Res. 2001;92: 1166-1174.","DOI":"10.1111\/j.1349-7006.2001.tb02136.x"},{"key":"2019111711055567100_REF37","doi-asserted-by":"crossref","unstructured":"Walker IG, Yatscoff RW, Sridhar R. Hydroxyurea: induction of breaks in template strands of replicating DNA. Biochem Biophys Res Commun. 1977;77: 403-408.","DOI":"10.1016\/S0006-291X(77)80212-X"},{"key":"2019111711055567100_REF38","unstructured":"Coyle MB, Strauss B. Cell killing and the accumulation of breaks in the DNA of HEp-2 cells incubated in the presence of hydroxyurea. Cancer Res. 1970;30: 2314-2319."},{"key":"2019111711055567100_REF39","doi-asserted-by":"crossref","unstructured":"Koeffler HP, Ranyard J, Pertcheck M. Myeloperoxidase: its structure and expression during myeloid differentiation. Blood. 1985;65: 484-491.","DOI":"10.1182\/blood.V65.2.484.484"},{"key":"2019111711055567100_REF40","doi-asserted-by":"crossref","unstructured":"Nu\u0308sing RM, Barsig J. Induction of prostanoid, nitric oxide, and cytokine formation in rat bone marrow derived macrophages by activin A. Br J Pharmacol. 1999;127: 919-926.","DOI":"10.1038\/sj.bjp.0702626"},{"key":"2019111711055567100_REF41","doi-asserted-by":"crossref","unstructured":"Rocca B, Secchiero P, Ciabattoni G, et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and charcaterizes newly formed platelets. Proc Natl Acad Sci U S A. 2002;99: 7634-7639.","DOI":"10.1073\/pnas.112202999"},{"key":"2019111711055567100_REF42","doi-asserted-by":"crossref","unstructured":"Furtmu\u0308ller PG, Arnhold J, Jantschko W, Pichler H, Obinger C. Redox properties of the couples compound I\/compound II and compound II\/native enzyme of human myeloperoxidase. Biochem Biophys Res Commun. 2003;301: 551-557.","DOI":"10.1016\/S0006-291X(02)03075-9"},{"key":"2019111711055567100_REF43","doi-asserted-by":"crossref","unstructured":"Hua J, Hasebe T, Someya A, Nakamura S, Sugimoto K, Nagaoka I. Evaluation of the expression of NADPH oxidase components during maturation of HL-60 cells to neutrophil lineage. J Leukoc Biol. 2000;68: 216-224.","DOI":"10.1189\/jlb.68.2.216"},{"key":"2019111711055567100_REF44","doi-asserted-by":"crossref","unstructured":"Pedruzzi E, Fay M, Elbim C, Gaudry M, Gougerot-Pocidalo M-A. Differentiation of PLB-985 myeloid cells into mature neutrophils, shown by degranulation of terminally differentiated compartments in response to N-formyl peptide and priming of superoxide anion production by granulocyte-macrophage colony-stimulating factor. Br J Haematol. 2002;117: 719-726.","DOI":"10.1046\/j.1365-2141.2002.03521.x"},{"key":"2019111711055567100_REF45","doi-asserted-by":"crossref","unstructured":"Ohshima H. Genetic and epigenetic damage induced by reactive nitrogen species: implications in carcinogenesis. Toxicol Lett. 2003;140-141: 99-104.","DOI":"10.1016\/S0378-4274(02)00506-4"},{"key":"2019111711055567100_REF46","doi-asserted-by":"crossref","unstructured":"Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem. 1996;271: 33157-33160.","DOI":"10.1074\/jbc.271.52.33157"},{"key":"2019111711055567100_REF47","doi-asserted-by":"crossref","unstructured":"Lassmann G, Curtis J, Liermann B, Mason RP, Eling TE. ESR studies on reactivity of protein-derived tyrosyl radicals formed by prostaglandin H synthase and ribonucleotide reductase. Arch Biochem Biophys. 1993;300: 132-136.","DOI":"10.1006\/abbi.1993.1018"},{"key":"2019111711055567100_REF48","doi-asserted-by":"crossref","unstructured":"Halsey C, Roberts IAG. The role of hydroxyurea in sickle cell disease. Brit J Haematol. 2003;120: 177-186.","DOI":"10.1046\/j.1365-2141.2003.03849.x"},{"key":"2019111711055567100_REF49","doi-asserted-by":"crossref","unstructured":"Cokic VP, Smith RD, Beleslin-Cokic BB, et al. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest. 2003;111: 231-239.","DOI":"10.1172\/JCI200316672"},{"key":"2019111711055567100_REF50","doi-asserted-by":"crossref","unstructured":"Glover RE, Ivy ED, Orringer EP, Maeda H, Mason RP. Detection of nitrosyl hemoglobin in venous blood in the treatment of sickle cell anemia with hydroxyurea. Molec Pharmacol. 1999;155: 1006-1010.","DOI":"10.1124\/mol.55.6.1006"},{"key":"2019111711055567100_REF51","doi-asserted-by":"crossref","unstructured":"Lockamy VL, Huang J, Shields H, Ballas SK, King SB, Kim-Shapiro DB. Urease enhances the formation of iron nitrosyl hemoglobin in the presence of hydroxurea. Biochim Biophys Acta. 2003;1622: 109-116.","DOI":"10.1016\/S0304-4165(03)00132-6"},{"key":"2019111711055567100_REF52","doi-asserted-by":"crossref","unstructured":"Pirozzi SJ, Renz JF, Kalf GF. The prevention of benzene-induced genotoxicity in mice by indomethacin. Mutation Res. 1989;222: 291-298.","DOI":"10.1016\/0165-1218(89)90146-8"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/6\/2219\/1286100\/zh800606002219.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/6\/2219\/1286100\/zh800606002219.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T10:30:50Z","timestamp":1683282650000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/107\/6\/2219\/22041\/Nitric-oxide-generation-from-hydroxyurea"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,15]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,3,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-08-3429","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,15]]}}}